<DOC>
	<DOC>NCT00690638</DOC>
	<brief_summary>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T as Monotherapy in Subjects with Type 2 Diabetes Mellitus</brief_summary>
	<brief_title>Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Type 2 diabetes mellitus, drug na√Øve or willing to washout from existing oral therapy BMI 25 to 48 kg/m2, inclusive HbA1c 7.0% 10.0%, inclusive Age 18 to 75 years, inclusive Currently on 3 or more oral antidiabetic drugs or insulin. Type 1 diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>dutogliptin</keyword>
	<keyword>PHX1149</keyword>
	<keyword>DPP4 inhibitor</keyword>
</DOC>